Skip to main content

Sarepta Therapeutics, Inc.

corporate_fare Company Profile

Sarepta Therapeutics, Inc.

SRPT·NASDAQ·Life Sciences·CIK 0000873303

We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. We apply our proprietary, differentiated, and innovative technologies, and collaborate with strategic partners. We have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD. We are also developing potential therapeutic candidates through our partnered program with Arrowhead for the treatment of Facioscapulohumeral muscular dystrophy ("FSHD"), myotonic dystrophy type 1 ("DM1"), Spinocerebellar ataxia ("SCA"), Idiopathic Pulmonary Fibrosis ("IPF"), Huntington's disease, and other neuromuscular and skeletal diseases. To date, we have developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen) Injection ("EXONDYS 51"), VYONDYS 53 (golodirsen) Injection ("VYONDYS 53"), AMONDYS 45 (casimersen) Injection ("AMONDYS 45"), and ELEVIDYS. We believe our proprietary technology platforms and collaborations can be used to develop novel pharmaceutical products to treat a broad range of diseases and address key currently-unmet medical needs.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for SRPT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for SRPT spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Sarepta Lifts 2026 Revenue Guidance Floor by $50M as ELEVIDYS Slides
  • Sarepta Q3 Revenue Slips 5% as ELEVIDYS Declines, but Guidance Low End Raised $50M
  • Sarepta Q3 2026: ELEVIDYS Revenue Falls 37% to $83.5M, Net Loss Narrows to $28.5M
  • ELEVIDYS Shows Durable Functional Benefit in Older Duchenne Patients, New Data Reveals
  • Sarepta Therapeutics Reaches Settlement Agreement with Regenxbio, UPenn, and Catalent

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.2B
Net Income
-$713.41M
Diluted EPS
-$7.13
Op. Cash Flow
-$205.48M
Free Cash Flow
-$307.45M
Gross Profit
$2.17B
Operating Income
-$699.78M
Cash & Equivalents
$801.28M
Total Debt
$828.97M
Debt / Equity
0.73×
Net Margin
-32.5%
Shares Outstanding
104.96M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-084144

Short Interest & Short Volume

7.82 days to cover

FINRA reported short interest of 19,297,522 shares in SRPT as of the October 30, 2026 settlement, a 13.6% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 43.2% of SRPT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,297,522 shares as of October 30, 2026
Change vs prior period▼ 13.6%
Days to cover7.82 at avg daily volume of 2,467,051
Daily short volume (FINRA facilities)43.2% of 861,693 shares on November 20, 2026
5-day average short volume45.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$13.6 +2.03% today
52-week range · as of 2026-11-05 $13.6 – $24.68
Market cap
$1.43B
Volume
2.3M (0.9× avg)
3-mo avg 2.4M
Live data · 2026-11-21 02:00 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.93
Real-time Price: $13.60 info
Change: -$4.33 (-24%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.65
Real-time Price: $13.60 info
Change: -$3.05 (-18%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.57
Real-time Price: $13.60 info
Change: -$3.97 (-23%) info
Market Cap: $1.429B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.60 info
Change: -$5.04 (-27%) info
Market Cap: $1.429B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.60 info
Change: -$5.43 (-29%) info
Market Cap: $1.429B info
SRPT
Jul 27, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.35
Real-time Price: $13.60 info
Change: -$2.75 (-17%) info
Market Cap: $1.429B info
SRPT
Jun 30, 2026, 8:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $17.30
Real-time Price: $13.60 info
Change: -$3.70 (-21%) info
Market Cap: $1.429B info
SRPT
Jun 04, 2026, 4:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.74
Real-time Price: $13.60 info
Change: -$3.14 (-19%) info
Market Cap: $1.429B info
SRPT
May 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.95
Real-time Price: $13.60 info
Change: -$8.35 (-38%) info
Market Cap: $1.429B info
SRPT
May 06, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.20
Real-time Price: $13.60 info
Change: -$9.60 (-41%) info
Market Cap: $1.429B info
SRPT
Mar 16, 2026, 8:39 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.61
Real-time Price: $13.60 info
Change: -$3.01 (-18%) info
Market Cap: $1.429B info
SRPT
Mar 02, 2026, 7:02 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $16.50
Real-time Price: $13.60 info
Change: -$2.90 (-18%) info
Market Cap: $1.429B info
SRPT
Feb 25, 2026, 5:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.35
Real-time Price: $13.60 info
Change: -$4.75 (-26%) info
Market Cap: $1.429B info
SRPT
Feb 25, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.25
Real-time Price: $13.60 info
Change: -$4.65 (-25%) info
Market Cap: $1.429B info
SRPT
Jan 12, 2026, 12:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $13.60 info
Change: -$7.52 (-36%) info
Market Cap: $1.429B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets